← Leaderboards
Bradley Maron
Brigham And Women'S Hospital
$8,442,424
Attributed
$11,226,477
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,226,477 · 7
By mechanism
R01$9,740,578 · 4
K08$754,110 · 1
R56$444,928 · 1
R21$286,861 · 1
Top collaborators
- Evan L Brittain4 shared
- Anna R Hemnes4 shared
- Sirano Dhe-Paganon3 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Farbod Nicholas Rahaghi$4,904,428
- James Kuang-Jan Liao$22,168,806
- Xuwen Wang$567,000
- Sirano Dhe-Paganon$892,205
- Benjamin Alexander Raby$29,217,666
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungBlood VesselsProteinsMortalityPulmonary Arterial HypertensionMolecularFibrosisInnovationHemodynamicsCessation Of LifeHeart DiseasesPathway InteractionsVascular RemodelingUnited States National Institutes Of HealthMediatingComplexProtein Protein InteractionArterial RemodelingIn VivoPharmaceutical PreparationsMedicinePhenotypeBindingIn Vitro
Grant awards (28)
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$699,718
R01 · FY2025 · HL
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension$576,691
R01 · FY2025 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$685,723
R01 · FY2024 · HL
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension$570,887
R01 · FY2024 · HL · contact PI
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension$374,442
R01 · FY2024 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$653,505
R01 · FY2023 · HL
Targeting FAK-NEDD9 protein-protein interaction to prevent focal adhesion assembly and vascular proliferation in pulmonary arterial hypertension$636,832
R01 · FY2023 · HL · contact PI
NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertension$432,332
R01 · FY2023 · HL · contact PI
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension$286,679
R01 · FY2023 · HL · contact PI
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension$128,901
R01 · FY2023 · HL · contact PI
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary Hypertension$798,826
R01 · FY2022 · HL
NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertension$432,332
R01 · FY2022 · HL · contact PI
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension$415,581
R01 · FY2022 · HL · contact PI
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension$435,331
R01 · FY2021 · HL · contact PI
NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertension$432,332
R01 · FY2021 · HL · contact PI
Systems biology, endothelial regulation of fibrosis, and pulmonary vascular disease$432,096
R01 · FY2021 · HL · contact PI
NEDD9-SMAD3, fibrinolysis, and chronic thromboembolic pulmonary hypertension$432,332
R01 · FY2020 · HL · contact PI
Systems biology, endothelial regulation of fibrosis, and pulmonary vascular disease$432,096
R01 · FY2020 · HL · contact PI
Network medicine, risk stratification, and pulmonary hypertension$123,470
R21 · FY2020 · HL · contact PI
Systems biology, endothelial regulation of fibrosis, and pulmonary vascular disease$435,314
R01 · FY2019 · HL · contact PI
Network medicine, risk stratification, and pulmonary hypertension$163,391
R21 · FY2019 · HL · contact PI
Systems biology, endothelial regulation of fibrosis, and pulmonary vascular disease$448,628
R01 · FY2018 · HL · contact PI
Fibrosome regulation by aldosterone in pulmonary vascular disease$444,928
R56 · FY2017 · HL · contact PI
Aldosterone impairs endothelin B-dependent synthesis of nitric oxide to promote p$172,800
K08 · FY2017 · HL · contact PI
Aldosterone impairs endothelin B-dependent synthesis of nitric oxide to promote p$172,800
K08 · FY2016 · HL · contact PI
Aldosterone impairs endothelin B-dependent synthesis of nitric oxide to promote p$136,170
K08 · FY2015 · HL · contact PI
Aldosterone impairs endothelin B-dependent synthesis of nitric oxide to promote p$136,170
K08 · FY2014 · HL · contact PI
Aldosterone impairs endothelin B-dependent synthesis of nitric oxide to promote p$136,170
K08 · FY2013 · HL · contact PI